Literature DB >> 17096085

Selective depletion of cortical noradrenaline by anti-dopamine beta-hydroxylase-saporin impairs attentional function and enhances the effects of guanfacine in the rat.

Jean A Milstein1, Olivia Lehmann, David E H Theobald, Jeffrey W Dalley, Trevor W Robbins.   

Abstract

RATIONALE: Previous data indicate that depletion of cortical noradrenaline (NA) impairs performance of an attentional five-choice serial reaction time task (5CSRT) under certain conditions. This study employed a novel immunotoxin, anti-dopamine-beta hydroylase (DbetaH)-saporin, to make relatively selective lesions of the noradrenergic projections to the prefrontal cortex (PFC) in rats trained to perform the 5CSRT.
OBJECTIVES: The aim of this work is to examine (1) the effect of cortical noradrenaline depletion on sustained attentional performance in the 5CSRT under a variety of test conditions and (2) the effects of guanfacine, a selective alpha-2 adrenoceptor agonist on attentional performance in sham and NA-depleted rats.
MATERIALS AND METHODS: Animals received either intramedial prefrontal anti-DbetaH-saporin or vehicle and were tested on the baseline task with a variety of additional manipulations including (1) decreasing target duration, (2) increasing rate and (3) temporal unpredictability of target presentation and (4) systemic guanfacine.
RESULTS: Anti-DbetaH-saporin infused into the PFC produced a substantial loss of DbetaH-positive fibers in that region and in other adjacent cortical areas. There was no significant depletion of DA or 5-HT. NA-depleted animals were not impaired on the baseline task, but were slower to respond correctly under high event rate conditions, and their discriminative accuracy was reduced when stimulus predictability decreased. Guanfacine significantly reduced discriminative accuracy in NA-depleted animals only.
CONCLUSION: Selective cortical NA depletion produced deficits on the 5CSRT test of sustained attention, especially when the attentional load was increased and in response to systemic guanfacine. These results are consistent with a role of coeruleo-cortical NA in the regulation of effortful attentional processes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17096085      PMCID: PMC1892793          DOI: 10.1007/s00213-006-0594-x

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  37 in total

Review 1.  Role of locus coeruleus in attention and behavioral flexibility.

Authors:  G Aston-Jones; J Rajkowski; J Cohen
Journal:  Biol Psychiatry       Date:  1999-11-01       Impact factor: 13.382

2.  Alpha-2 adrenoceptor activation inhibits phencyclidine-induced deficits of spatial working memory in rats.

Authors:  William Marrs; Julie Kuperman; Tahlin Avedian; Robert H Roth; J David Jentsch
Journal:  Neuropsychopharmacology       Date:  2005-08       Impact factor: 7.853

3.  Characterization of noradrenaline release in the locus coeruleus of freely moving awake rats by in vivo microdialysis.

Authors:  Begoña Fernández-Pastor; Yolanda Mateo; Sonia Gómez-Urquijo; J Javier Meana
Journal:  Psychopharmacology (Berl)       Date:  2005-02-17       Impact factor: 4.530

4.  Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability.

Authors:  M D S Lapiz; D A Morilak
Journal:  Neuroscience       Date:  2005-11-17       Impact factor: 3.590

5.  Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex.

Authors:  S Granon; F Passetti; K L Thomas; J W Dalley; B J Everitt; T W Robbins
Journal:  J Neurosci       Date:  2000-02-01       Impact factor: 6.167

6.  Effects of clonidine in the locus coeruleus on prefrontal- and hippocampal-dependent measures of attention and memory in the rat.

Authors:  Robert D Mair; Yueping Zhang; Kathleen R Bailey; Margaret M Toupin; Robert G Mair
Journal:  Psychopharmacology (Berl)       Date:  2005-04-14       Impact factor: 4.530

7.  Determination of the somatodendritic alpha2-adrenoceptor subtype located in rat locus coeruleus that modulates cortical noradrenaline release in vivo.

Authors:  Y Mateo; J J Meana
Journal:  Eur J Pharmacol       Date:  1999-08-20       Impact factor: 4.432

8.  Guanfacine, but not clonidine, improves planning and working memory performance in humans.

Authors:  P Jäkälä; M Riekkinen; J Sirviö; E Koivisto; K Kejonen; M Vanhanen; P Riekkinen
Journal:  Neuropsychopharmacology       Date:  1999-05       Impact factor: 7.853

9.  Treatment with the noradrenergic alpha-2 agonist clonidine, but not diazepam, improves spatial working memory in normal young rhesus monkeys.

Authors:  J S Franowicz; A F Arnsten
Journal:  Neuropsychopharmacology       Date:  1999-11       Impact factor: 7.853

10.  Lack of effects of guanfacine on executive and memory functions in healthy male volunteers.

Authors:  Ulrich Müller; Luke Clark; Minh L Lam; Rebecca M Moore; C Louise Murphy; Nicola K Richmond; Ranbir S Sandhu; Ingrid A Wilkins; David K Menon; Barbara J Sahakian; Trevor W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

View more
  47 in total

1.  Stress and alcohol cues exert conjoint effects on go and stop signal responding in male problem drinkers.

Authors:  Martin Zack; Tracy M Woodford; Anne M Tremblay; Lindsay Steinberg; Laurie A Zawertailo; Usoa E Busto
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

Review 2.  Neuropsychopharmacology and neurogenetic aspects of executive functioning: should reward gene polymorphisms constitute a diagnostic tool to identify individuals at risk for impaired judgment?

Authors:  Abdalla Bowirrat; Thomas J H Chen; Marlene Oscar-Berman; Margaret Madigan; Amanda Lh Chen; John A Bailey; Eric R Braverman; Mallory Kerner; John Giordano; Siobhan Morse; B William Downs; Roger L Waite; Frank Fornari; Zaher Armaly; Kenneth Blum
Journal:  Mol Neurobiol       Date:  2012-02-28       Impact factor: 5.590

3.  α₂- and β-adrenoceptors involvement in nortriptyline modulation of auditory sustained attention and impulsivity.

Authors:  Swagata Roychowdhury; Zulma Peña-Contreras; Jason Tam; Amulya Yadlapalli; Lu Dinh; Justin Andrew Nichols; Debarshi Basu; Marco Atzori
Journal:  Psychopharmacology (Berl)       Date:  2012-01-21       Impact factor: 4.530

4.  Noradrenergic innervation of the dorsal medial prefrontal cortex modulates hypothalamo-pituitary-adrenal responses to acute emotional stress.

Authors:  Jason J Radley; Brandon Williams; Paul E Sawchenko
Journal:  J Neurosci       Date:  2008-05-28       Impact factor: 6.167

Review 5.  Prefrontal cortex executive processes affected by stress in health and disease.

Authors:  Milena Girotti; Samantha M Adler; Sarah E Bulin; Elizabeth A Fucich; Denisse Paredes; David A Morilak
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-07-06       Impact factor: 5.067

6.  Modeling deficits in attention, inhibition, and flexibility in HAND.

Authors:  Landhing M Moran; Rosemarie M Booze; Charles F Mactutus
Journal:  J Neuroimmune Pharmacol       Date:  2014-04-25       Impact factor: 4.147

7.  Noradrenergic modulation of risk/reward decision making.

Authors:  David R Montes; Colin M Stopper; Stan B Floresco
Journal:  Psychopharmacology (Berl)       Date:  2015-03-13       Impact factor: 4.530

8.  Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex.

Authors:  Lori A Newman; Jenna Darling; Jill McGaughy
Journal:  Psychopharmacology (Berl)       Date:  2008-06-22       Impact factor: 4.530

9.  Noradrenergic, but not cholinergic, deafferentation of prefrontal cortex impairs attentional set-shifting.

Authors:  J McGaughy; R S Ross; H Eichenbaum
Journal:  Neuroscience       Date:  2008-02-19       Impact factor: 3.590

Review 10.  Is there an inhibitory-response-control system in the rat? Evidence from anatomical and pharmacological studies of behavioral inhibition.

Authors:  Dawn M Eagle; Christelle Baunez
Journal:  Neurosci Biobehav Rev       Date:  2009-07-15       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.